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Abstract 
Coronavirus disease 2019 (COVID-19) is emerging as the greatest public health crisis in the early 21st century. Its 
causative agent, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), is an enveloped single-
stranded positive-sense ribonucleic acid virus that enters cells via the angiotensin converting enzyme 2 receptor 
or several other receptors. While COVID-19 primarily affects the respiratory system, other organs including the 
brain can be involved. In Western clinical studies, relatively mild neurological dysfunction such as anosmia and 
dysgeusia is frequent (~70-84%) while severe neurologic disorders such as stroke (~1-6%) and meningoenceph-
alitis are less common. It is unclear how much SARS-CoV-2 infection contributes to the incidence of stroke given 
co-morbidities in the affected patient population. Rarely, clinically-defined cases of acute disseminated enceph-
alomyelitis, Guillain-Barré syndrome and acute necrotizing encephalopathy have been reported in COVID-19 pa-
tients. Common neuropathological findings in the 184 patients reviewed include microglial activation (42.9%) 
with microglial nodules in a subset (33.3%), lymphoid inflammation (37.5%), acute hypoxic-ischemic changes 
(29.9%), astrogliosis (27.7%), acute/subacute brain infarcts (21.2%), spontaneous hemorrhage (15.8%), and mi-
crothrombi (15.2%). In our institutional cases, we also note occasional anterior pituitary infarcts. COVID-19 co-
agulopathy, sepsis, and acute respiratory distress likely contribute to a number of these findings. When present, 
central nervous system lymphoid inflammation is often minimal to mild, is detected best by immunohistochem-
Review 
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istry and, in one study, indistinguishable from control sepsis cases. Some cases evince microglial nodules or neu-
ronophagy, strongly supporting viral meningoencephalitis, with a proclivity for involvement of the medulla ob-
longata. The virus is detectable by reverse transcriptase polymerase chain reaction, immunohistochemistry, or 
electron microscopy in human cerebrum, cerebellum, cranial nerves, olfactory bulb, as well as in the olfactory 
epithelium; neurons and endothelium can also be infected. Review of the extant cases has limitations including 
selection bias and limited clinical information in some cases. Much remains to be learned about the effects of 
direct viral infection of brain cells and whether SARS-CoV-2 persists long-term contributing to chronic sympto-
matology. 
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1. Introduction 
In late 2019, a novel infectious disease associ-
ated with pneumonia and acute respiratory distress 
emerged in Wuhan, China. The implicated human 
coronavirus was genetically related to but distinct 
from the underlying viral agent behind the 2003 Se-
vere Acute Respiratory Syndrome (SARS) outbreak, 
SARS coronavirus (SARS-CoV). The International 
Committee of Taxonomy of Viruses designated this 
novel coronavirus as Severe Acute Respiratory Syn-
drome coronavirus 2 (SARS-CoV-2)1 and the World 
Health Organization termed the associated disease 
as coronavirus disease 2019 (COVID-19).1 As unsus-
pecting asymptomatic patients readily spread the 
disease, the COVID-19 pandemic has swept rapidly 
across the world resulting, by the end of December 
2020, in over 79 million confirmed human infections 
and over 1.7 million deaths.2 These numbers are be-
lieved to be substantial underestimates of the true 
toll. COVID-19 is best known for its pulmonary in-
volvement, but other organs are often affected in-
cluding heart, kidney and nervous system. This re-
view will provide an overview of tissue-based 
COVID-19 neuropathological analyses, almost en-
tirely autopsy derived, as well as a brief discussion 
of SARS-CoV-2 virology to provide context for under-
standing its pathogenesis, and of diagnostic testing 
limitations that may bias the examined cases. The 
nervous system is affected both secondarily from 
systemic complications such as hypoxia and coag-
ulopathy, and also likely from primary infection 
though much remains to be elucidated regarding vi-
ral invasion of the brain, spinal cord and other com-
ponents of the nervous system. 
2. SARS-CoV-2 virology 
SARS-CoV-2 is the latest coronavirus to emerge 
as a human pathogen. Coronaviruses are single-
stranded, positive-sensed ribonucleic acid (RNA) vi-
ruses subdivided into four genera: alpha-corona-
virus (α-CoV), beta-coronavirus (β-CoV), gamma-
coronavirus (γ-CoV), and delta-coronavirus (δ-CoV).3 
SARS-CoV-2 is a beta-coronavirus, typically 60 to 140 
nm4–6 in size, that shares genetic similarities to SARS-
CoV (~79% homology) and Middle East Respiratory 
Syndrome coronavirus (MERS-CoV) (~50% homol-
ogy).7 The SARS-CoV-2 genome encodes 16 non-
structural proteins involved in viral replication and 
four structural proteins consisting of the envelope, 
membrane, nucleocapsid, and spike glycoprotein 
(Figure 1).3,8,9 The virus is constantly evolving with 
numerous strains of SARS-CoV-2 identified, some 
preferentially localized (at least temporarily) to geo-
graphic regions such as Europe or North America.10 
The mutation rate of SARS-CoV-2 is estimated to be 
0.84-1.12 x 10-3 substitutions per site per year,7,11 
which is lower than that of human immunodefi-
ciency virus (HIV)12 or influenza A.13 The genetic 
spectrum of disparate SARS-CoV-2 strains undergo-
ing continued mutation could contribute to the var-
iability of neuropathological findings discussed later. 
Antibodies against nucleocapsid and spike proteins 
have been used for immunohistochemical studies. 
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Figure 1: Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) structure. There are four structural proteins: spike (S) protein (red), enve-
lope (E) protein (violet), membrane (M) protein (blue), and nucleocapsid (N) protein (orange). 
 
 
3. ACE2 and other receptors mediate 
SARS-CoV-2 entry 
The entry of SARS-CoV-2 into human cells is 
commonly thought to be mediated by the interac-
tion of the spike protein with the angiotensin con-
verting enzyme 2 (ACE2) receptor, an important reg-
ulator of the renin-angiotensin system (RAS).14 Gen-
der, age, lifestyle, smoking, and other patient co-
morbidities are implicated in the modulation of 
ACE2 receptor expression in various tissues.15–21 
ACE2 receptor expression has been reported in the 
cerebrum, cerebellum, brainstem, retina, and olfac-
tory mucosa.22–24 Neurons, vascular pericytes and 
smooth muscle, and glia express the ACE2 recep-
tor.22,23,25 In addition to the ACE2 receptor, in vitro 
studies show that SARS-CoV-2 may gain entry using 
other cell receptors, such as basigin (BSG; CD147),26 
neuropilin-1 (NRP1),27 transmembrane serine prote-
ase 2 and 4 (TMPRSS2/4),28,29 and cathepsin L 
(CTSL).9 Expression of ACE2 receptor is highest in ol-
igodendrocytes, TMPRSS2/4 in neurons, CTSL in mi-
croglia, and NRP1 in endothelial cells.25 In principle 
therefore, a broad range of cells in the central nerv-
ous system (CNS) have a variety of receptors that 
may facilitate infection. 
4. Laboratory testing for COVID-19 has 
significant limitations 
In part due to the natural course of disease 
wherein viral titers rise over time, laboratory testing 
for SARS-CoV-2 does not completely exclude patient 
infection, complicating the neuropathologist’s man-
agement of surgical or autopsy cases. There may 
also be a bias towards evaluating autopsies of 
COVID-19 patients with severe disease and high viral 
loads. The analytical sensitivity of the commonly 
used COVID-19 reverse transcriptase polymerase 
chain reaction (RT-PCR) assay is excellent with a limit 
of detection as low as 6.25 copies/µL in a nasopha-
ryngeal sample.30 In a clinical setting, the sensitivity 
of RT-PCR may be 83.3% or significantly less, and 
may be affected by infection phase, sample type, 
collection procedures, and testing platforms.31,32 
COVID-19 RT-PCR testing may produce false-
negative results in the initial phase of infection. In 
sequential testing of patients who have symptoms, 
suspicious chest computed tomography (CT) find-
ings and an initial negative RT-PCR test, COVID-19 
RT-PCR positivity occurs at a mean of 5.1 ± 1.5 days 
after the initial test.32 A patient with a negative RT-
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PCR test result in a nasopharyngeal swab but with a 
positive SARS-CoV-2 cerebrospinal fluid (CSF) test 
has been reported.33 While RT-PCR detection of ge-
nomic RNA is not specific for viable virus, identifica-
tion of sub-genomic RNAs transcribed in infected 
cells have been used in clinical testing to document 
the presence of actively replicating virus in lieu of vi-
ral cultures.34 Although chest CT scans may detect 
signs of COVID-19 days before RT-PCR positivity, CT 
findings overlap with other viral pneumonias.35 
Serologic testing has uses for contact tracing, 
epidemiology, and vaccine studies but is more chal-
lenging to use for primary diagnosis given the la-
tency for development of antibodies.36–40 The most 
common serological assays are the rapid lateral flow 
assay, enzyme linked immunosorbent assay (ELISA), 
and virus neutralization assay. Two-step ELISA as-
says are quantitative and more reliable than flow as-
says that are easily scalable but are qualitative.40 The 
virus neutralization assay detects and quantifies an-
tibodies that inhibit viral replication but is techni-
cally complex.37 
5. Systemic pathophysiology of 
COVID-19 
In the first stage of infection, SARS-CoV-2 tar-
gets nasal and bronchial epithelial cells as well as 
pneumocytes.28 As infection progresses, SARS-CoV-
2 infects pulmonary endothelial cells, abrogating the 
epithelial-endothelial barrier.41 A subsequent in-
gress of neutrophils and monocytes is followed by 
pulmonary edema and hyaline membrane for-
mation, a component of early acute respiratory dis-
tress syndrome (ARDS).41,42 In severe COVID-19, co-
agulopathy can occur, reflecting microthrombi for-
mation secondary to endothelial cell inflammation 
and cytokine storms.41,43 COVID-19 associated hy-
percoagulability induces venous thromboembolism 
and arterial occlusion.41 The interplay of these sys-
temic derangements likely contributes to the patho-




Figure 2: Flow chart modeling COVID-19 pathogenesis and neurological dysfunction. ADEM= Acute disseminated encephalomyelitis; ANE= 
Acute necrotizing encephalopathy; GBS= Guillain-Barré syndrome. 
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6. COVID-19 neurological manifesta-
tions 
COVID-19 associated neurological manifesta-
tions range from mild symptoms such as dizziness, 
headache, dysgeusia, or anosmia to severe disorders 
such as stroke, Guillain-Barré syndrome (GBS), acute 
hemorrhagic necrotizing encephalopathy, menin-
goencephalitis, and cerebral venous thrombosis. 
The frequency of reported neurological signs and 
symptoms is variable but substantial regardless. In 
an early Chinese retrospective study, 36.4% of 214 
COVID-19 patients had neurological symptoms 
which included dizziness (16.8%), headache (13.1%), 
impaired consciousness (7.5%), dysgeusia (5.6%), 
and anosmia (5.1%).44 In Western studies, dysgeusia 
and anosmia are reported in the majority of pa-
tients.45,46 A French study reports that 49 out of 58 
(84%) COVID-19 intensive care unit (ICU) patients 
had neurological signs which included agitation 
(69%), confusion (65%), corticospinal tract signs 
(67%), and dysexecutive syndrome (33%).47 A study 
from a British referral center also describes cases of 
septic or para-infectious encephalopathy, autoim-
mune encephalitis including acute disseminated en-
cephalomyelitis (ADEM), and GBS.48 
7. Specific neurological disorders asso-
ciated with COVID-19 
Olfactory and gustatory dysfunction 
In the aforementioned study from China, 
COVID-19 patients had gustatory dysfunction and ol-
factory dysfunction at frequencies of less than 6% 
each.44 In a prospective European study, 88.8% of 
385 COVID-19 patients had gustatory dysfunction 
and 85.6% of 417 COVID-19 patients had olfactory 
dysfunction.45 In a California study, 71% of 59 
COVID-19 patients recorded ageusia and 68% re-
ported anosmia.46 Olfactory and gustatory dysfunc-
tion in COVID-19 typically resolves after 17 to 30 
days from initial onset.49,50 Although long term fol-
low-up is generally lacking,51 one study reports res-
olution rates at day 30 in home-quarantined COVID-
19 patients of 87% for olfactory dysfunction and 
82% for gustatory dysfunction.52 Presence of SARS-
CoV-2 virions in the olfactory neuroepithelium of 
the nasal mucosa as well as in the olfactory bulb has 
been documented53,54 though the exact basis for ol-
factory dysfunction and recovery remains to be re-
solved. 
Stroke 
Stroke is the most common debilitating neuro-
logical disorder associated with COVID-19 and has a 
predilection for males and the elderly. Two retro-
spective New York studies reported respectively 
that 1.6% of 1,916 patients with hospitalizations or 
emergency department visits for COVID-19 and 0.9% 
of 3,556 hospitalized COVID-19 patients had radio-
logically-confirmed ischemic infarcts.55,56 Crypto-
genic strokes were twice as common in hospitalized 
COVID-19 patients compared to either contempo-
rary or historical controls.56 A third New York retro-
spective study found 1.1% of 3,218 COVID-19 pa-
tients had strokes; in the small subset with acute 
neuroimaging, 68.5% of strokes were ischemic 
(44.5% large vessel, 24% lacunar) and 24% were 
hemorrhagic.57 A retrospective Chinese study of 214 
COVID-19 patients reported strokes in six patients 
(2.8%).44 A small American case series reported large 
vessel ischemic strokes in five COVID-19 patients 
younger than 50, four of whom had no prior history 
of stroke.58 For comparison, the average incidence 
of stroke among patients admitted through a U.S. 
emergency department prior to the pandemic was 
approximately 3.2%.59 Of patients who visited emer-
gency departments or were hospitalized, only 0.2% 
of 1486 influenza patients had ischemic infarcts 
which was significantly less than COVID-19 patients 
even after adjusting for age, sex and, race.55 
In another New York study, 33 out of 755 
(4.4%) COVID-19 patients with neuroimaging had 
evidence of intracranial hemorrhage not associated 
with trauma, brain metastases, or tumor resec-
tion.60 Parenchymal hemorrhages with mass effect 
and herniation were present in five patients, punc-
tate hemorrhages in seven, small to moderate sized 
hemorrhages in 17, and large single site hemor-
rhages without herniation in four.60 Twenty-six of 
the 33 intracranial hemorrhages occurred as a trans-
formation of an ischemic infarct.60 Of the five pa-
tients with parenchymal hemorrhages, four had high 
partial thromboplastin time or anti-factor Xa in the 
72 hours before the intracranial hemorrhage.60 
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Advanced age, cardiovascular disease, cerebro-
vascular disease, diabetes, chronic respiratory dis-
ease, hypertension, obesity, smoking, and cancer 
are risk factors for severe COVID-19 disease or poor 
outcome.61–67 In a Canadian study, critically ill 
COVID-19 patients with blood groups A and AB were 
more likely to require ventilation, continuous renal 
replacement therapy, and prolonged intensive care 
unit admission.68 In contrast, an earlier American 
COVID-19 study did not show an association be-
tween specific blood groups and either ventilation 
or death.69 Differences in cohorts including mortality 
rates may account for the contradictory findings.68 It 
cannot escape notice that a number of the afore-
mentioned COVID-19 prognostic factors are associ-
ated with atherosclerosis and arteriolosclerosis that, 
in the setting of COVID-19 respiratory compromise 
and coagulopathy, may contribute to strokes. 
Guillain-Barré syndrome 
GBS is an uncommon, immune-mediated de-
myelinating disease of the peripheral nerves that of-
ten follows viral infections. Common presenting 
symptoms in COVID-19 patients include symmetrical 
flaccid quadriparesis, ataxia, facial weakness, respir-
atory failure, and lower paresthesia.70–72 RT-PCR of 
nasopharyngeal swabs tested positive for SARS-CoV-
2 but CSF was negative for tested patients.73–75 GBS 
symptoms tend to emerge between day five to 10 
after COVID-19 symptom onset.71 Over 30 cases of 
GBS have been reported.73–76 One proposed mecha-
nism is an autoimmune hyperreaction, triggering re-
lease of pro-inflammatory mediators such as inter-
leukin (IL)-6, that cause autoimmune demyelination 
or axonal damage. Alternatively in some cases, 
SARS-CoV-2 may induce production of antibodies 
targeting gangliosides, leading to peripheral neurop-
athy.72,77 COVID-19 associated Miller Fisher syn-
drome (MFS), a variant of GBS with ophthalmople-
gia, areflexia, and ataxia, and polyneuritis cranialis 
(PNC), a GBS variant with multiple cranial neuropa-
thies, have been reported.78 
Meningitis and encephalitis 
COVID-19 associated meningitis has only infre-
quently been reported but one case highlights the 
need for CSF testing if suspected.33 A 24-year-old 
Japanese male presented with headache, general-
ized fatigue and fever. Nine days after onset of typi-
cal COVID-19 symptoms, the patient had altered 
mental status, transient generalized seizures, and 
neck stiffness. Brain magnetic resonance imaging 
(MRI) showed hyperintensities along the lateral ven-
tricle and in the medial temporal lobe including the 
hippocampus. SARS-CoV-2 RNA was not detected by 
RT-PCR in a nasopharyngeal swab but was in CSF.33 
Autopsies performed on COVID-19 patients have 
suggested meningoencephalitis in some cases and 
these are discussed in section 8.79 
Other disorders 
A Brazilian study reported central venous 
thrombosis (CVT) in three previously healthy COVID-
19 patients younger than 41 years, underscoring the 
need for awareness of a hypercoagulable state in 
COVID-19 even in this age group.80 
Acute hemorrhagic necrotizing encephalopa-
thy, an uncommon complication characterized by 
multifocal symmetric brain lesions including bilat-
eral thalamic lesions, has been associated with 
COVID-19, though rarely.81,82 This complication may 
be caused by blood-brain-barrier disruption related 
to intracranial cytokine storms.81 COVID-19 associ-
ated cases of ADEM-like disease and autoimmune 
encephalitis have been documented.72,83 
8. Neuropathological findings and 
neuropathogenesis of COVID-19 
To examine the spectrum of COVID-19 neuro-
pathology, we reviewed 20 papers encompassing 
184 patients with tissue-based neuropathological 
analyses including 101 cases analyzed by RT-PCR for 
SARS-CoV-2 and 83 cases by immunohistochemistry 
(IHC) (Table 1).25,53,79,83–99 All cases are autopsies ex-
cept for four biopsies and one case of unspecified 
type. The range of histologic findings is broad and in 
part reflects the heterogeneity of neurological find-
ings. The most frequent findings (Table 1) include 
microglial activation with microglial nodules in a 
likely underestimated subset; lymphoid inflamma-
tion including perivascular lymphocytosis (Figure 
3a), parenchymal lymphocytic infiltration, and lep-
tomeningeal lymphocytic inflammation; hypoxic-is-
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chemic changes (Figure 3b); astrogliosis; acute/sub-
acute brain infarcts; primary hemorrhage; and mi-
crothrombi. It should be noted that the prevalence 
of detected lymphoid inflammation and microglial 
nodules is high in papers with immunohistochemical 
studies and low in those without. 
Table 1: Neuropathological findings in COVID-19 
brain tissue 
 
Table 1: Some histologic findings are likely to be under-reported 
as reviewed studies are variable in their focus. *Only studies 
tabulating the prevalence of microglial nodules are included. 
Studies mentioning microglial nodules in their case series but 
not enumerating the frequency are excluded. 
SARS-CoV-2 is detectable in central nervous sys-
tem tissue 
At least three routes of CNS infection by SARS-
CoV-2 have been proposed: retrograde transmission 
via olfactory sensory neurons, infiltration of immune 
cells, and entry across the blood-brain barrier.100,101 
The prevalence of anosmia and ageusia in COVID-19 
patients led to the theory that SARS-CoV-2 enters 
the brain via infection of neurons in the olfactory 
neuroepithelium (which resides in the mucosa of the 
nasal cavity) and from there to the olfactory bulb 
and then to other brain regions. This olfactory route 
is used by other coronaviruses, such as SARS-CoV102 
and MERS-CoV.103 COVID-19 patients frequently dis-
play MRI hyperintensity in the olfactory cortex.104 
The ACE2 receptor, used by SARS-CoV-2 for cellular 
entry, is expressed in sustentacular cells and stem 
cells of the nasal olfactory epithelium.23,105 While 
one study suggests olfactory neurons themselves do 
not express the ACE2 receptor,23 another report 
contradicts this finding.106 Besides technical sensitiv-
ity issues, it may be that the expression levels of the 
ACE2 receptor and other receptors differ under in-
flammatory conditions as compared to physiologic 
conditions. Viral particles have been detected by 
electron microscopy and IHC in the olfactory epithe-
lium54 as well as by electron microscopy in olfactory 
neurons of the nasal mucosa at autopsy.53 Morbini 
and colleagues report ultrastructural evidence of 
SARS-CoV-2 particles in the olfactory bulb of a 
COVID-19 patient.54 A second theory posits that 
SARS-CoV-2 may infect immune cells that cross the 
blood-brain barrier and deliver virus into the brain. 
This mechanism is well described in HIV.107 White 
blood cells including lymphocytes and monocytes 
express the ACE2 receptor.108,109 Infection of im-
mune cells by SARS-CoV-2 is an active area of study. 
Finally, the third theory extends the well docu-
mented behavior of encephalitic blood-borne coro-
naviruses to enter through the blood-brain barrier 
via infection of vessel wall cells.110 
Histologically, on routine hematoxylin- and eo-
sin-stained slides, neither viral inclusions nor spe-
cific cellular changes recognizable as direct viral in-
fection have been reported. However, SARS-CoV-2 
has been detected in the brain by RT-PCR, IHC, and 
electron microscopy. As many as 54 out of 101 
(53.5%) cases were positive for SARS-CoV-2 in the 
brain by RT-PCR and 23 out of 83 (27.7%) cases were 
positive by IHC (Table 1). In some cases, copies of vi-
rus detected by RT-PCR were low in number and the 
detection of virus in blood or blood cells within in-
tracerebral vasculature rather than brain cells was a 
possibility. However, IHC has confirmed the pres-
ence of viral antigens in autopsy brain cells. Of note, 
antibodies against SARS-CoV-2 spike protein were 
more effective in detecting viral antigens than those 
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Figure 3: Representative COVID-19 histopathology: a. Mild perivascular lymphoid inflammation, 400X (arrow); b. Eosinophilia in Purkinje 
cells compatible with acute hypoxic-ischemic change, 200X (arrows); c. Subacute infarct of anterior pituitary gland, 100X (arrows); d. 
Alzheimer Type II astrocytes in basal ganglia, 400X (circle). 
 
 
targeted against nucleocapsid protein25,87,97 (Supple-
mentary Table A). Importantly, staining using both 
anti-spike and anti-nucleocapsid antibodies may be 
more sensitive than either alone as, in a few cases, 
nucleocapsid protein was detected while spike pro-
tein was not. Whether this finding is a technical issue 
related to the quality of the antibodies or the intrin-
sic accessibility of the relevant epitopes or both is 
unresolved. Staining of virus localizes in scattered 
cortical neurons and endothelial cells,87 as well as 
brainstem cranial nerve roots and isolated cells (cell 
type unclear) in the medulla oblongata; the images 
of the isolated cells had a striking lack of attendant 
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chronic inflammation.25 This disconnect between vi-
ral infection and inflammation raises the question of 
immune evasion. One case exhibited viral staining 
around the edges of subcortical white matter mi-
croinfarcts.87 The immunostaining pattern consists 
of diffuse cytoplasmic and perinuclear positivity 
with small concentrated foci possibly representing 
viral inclusion bodies.87 Meinhardt and colleagues, 
using in situ hybridization (ISH), identified SARS-
CoV-2 in the olfactory epithelium and mucus.53 
Lastly, viral particles compatible with SARS-CoV-2 
have been identified by electron microscopy in ol-
factory bulb and frontal lobe tissue.54,96 To date, re-
gions in which SARS-CoV-2 have been detected by 
IHC, RT-PCR, or electron microscopy relevant to the 
CNS include cornea, conjunctiva, olfactory epithe-
lium, olfactory bulb, olfactory tubercle, frontal lobe, 
cerebellum, medulla oblongata, cranial nerves and 
trigeminal ganglion. Most investigations studied lim-
ited areas of brain or did not specify the origin of 
cerebral cortex tissue. Additional studies are needed 
to better establish the frequency and extent of di-
rect infection in the CNS. As some patients have 
"Long COVID” wherein they have persistent symp-
toms for months, whether and how SARS-CoV-2 may 
persist in the brain will need to be evaluated in the 
future. 
Chronic inflammatory and reactive glial changes 
Microgliosis and astrocytosis are common in 
COVID-19 brains including in the olfactory bulb.25 
Lymphoid inflammation, which tends to be minimal 
or mild in many cases, is not uncommon particularly 
in the medulla oblongata and if IHC is used for de-
tection.25 In many studies that did not use IHC, lym-
phoid inflammation was reported as absent or infre-
quent; this is concordant with our experience and 
anecdotally with that of colleagues in Asia and in the 
United States (personal communication). A substan-
tial portion of these reactive changes may be sec-
ondary to systemic issues (e.g. sepsis) or other neu-
ropathology (infarcts, hemorrhages, etc.) rather 
than a response to direct infection. Microgliosis and 
chronic inflammation did not correlate with the se-
verity of COVID-19 disease nor were there any dis-
cernible neuropathological differences in patients 
from nursing homes, hospital wards, or intensive 
care units.25 Furthermore, microglial activation, 
perivascular lymphocytosis, and leptomeningeal 
lymphocytic infiltration is observed to similar de-
grees in the control brains of septic (non-COVID-19) 
patients when compared to COVID-19 patients.86 
Some cases present findings compatible with 
viral meningoencephalitis including parenchymal 
lymphocytic clustering around microglial nodules, 
concomitant leptomeningeal lymphocytic inflam-
mation, and even neuronophagy. In the study by 
Matschke and colleagues, four out of 16 cases im-
munopositive for SARS-CoV-2 had 10 to 49 CD8+ cy-
totoxic T lymphocytes per high power field in at least 
three fields in the medulla oblongata.25 The ob-
served lymphocytes tended to cluster near activated 
microglial nodules,25 as commonly seen in viral en-
cephalitis. RT-PCR detected SARS-CoV-2 RNA in 
three out of the four cases.25 Three studies report 
neuronophagy in the medulla associated with histi-
ocytic and lymphocytic parenchymal infiltra-
tion.25,84,89 von Weyhern and colleagues report six 
cases of perivascular and parenchymal lymphocyto-
sis with neuronal loss and axon degeneration in the 
brainstem, which the authors determined to be ad-
equate to diagnose SARS-CoV-2 viral encephalitis.79 
In the same study, five of the six cases had concom-
itant meningitis.79 Respiratory and cardiovascular 
control centers of the medulla may be affected.53 
While the majority of COVID-19 patients with neuro-
logical manifestations do not have detectable SARS-
CoV-2 RNA in CSF by RT-PCR,111–113 exceptions to this 
trend have been reported in at least four COVID-19 
patients.33,114–116 Anti-SARS-CoV-2 antibodies were 
detected in the CSF of one COVID-19 patient sug-
gesting an immune response to viral infection.87 It 
appears therefore that histologically documentable 
cases of SARS-CoV-2 encephalitis and/or meningitis 
do occur, with a tendency to involve the brainstem. 
As only a few series report the majority of brainstem 
microglial encephalitis cases, the question arises as 
to whether particular viral strains, therapeutic ap-
proaches, genetic background or detection methods 
are responsible for its apparent absence or paucity 
in the majority of studies. 
Autoimmune mediated inflammation may also 
occur. Autoimmune encephalitis, ADEM, and acute 
necrotizing encephalopathy have also been re-
ported clinically though histopathologic evaluation 
has been limited. ADEM-like pathology has been re-
ported in one autopsy case.83 
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Microthrombi, infarcts, hemorrhages, and “neu-
trophilic plugs” 
SARS-CoV-2 may induce a cytokine storm, a se-
vere hyperimmune reaction characterized by exces-
sive and rapid release of cytokines such as IL-6 and 
IL-1β into the blood.117,118 IL-6 activates the coagula-
tion system and increases vascular permeability119 
which, in combination with viral endotheliopathy,120 
may account for the well documented COVID-19 as-
sociated coagulopathy.41,121 SARS-CoV-2 has been 
detected within cerebral endothelial cells by IHC and 
electron microscopy.87,96 Hypercoagulability, in turn, 
results in histologic findings of microthrombi, in-
farcts, and hemorrhages. Also, IL-1β plays a major 
role in triggering vascular “neutrophilic plugs” con-
taining neutrophils and/or platelets as well as neu-
trophil extracellular traps, a mesh of deoxynucleic 
acid (DNA)-rich material coated with antimicrobials 
that entrap and kill microbes.122 These “neutrophilic 
plugs” have been found in the brain as well as the 
lungs, heart, kidneys, and liver of COVID-19 patients 
who come to autopsy.88 Approximately 1.6% of 
cases have “neutrophilic plugs” in the brain (Table 1) 
though this percentage is likely an underestimate as 
pathologists do not typically evaluate for these 
structures. Pneumonia and ARDS with resultant hy-
poxemia as well as pre-existing arteriosclerosis are 
also likely contributory to the cerebral infarcts. In 
addition to cerebral infarcts, we have noted occa-
sional cases of pituitary infarcts (Figure 3c) in our 
COVID-19 autopsies. Numerous extramedullary 
megakaryocytes were present in subacute cerebral 
infarcts of one COVID-19 patient.84 
Alzheimer Type II astrocytosis 
Alzheimer Type II astrocytosis (Figure 3d) char-
acteristic of hepatic encephalopathy has been re-
ported.89,97 The reports do not specify whether the 
frequency of the Alzheimer Type II astrocytes 
reaches a threshold of five or more per 20 high 
power fields, the cutoff suggested by Agarwal and 
colleagues for hepatic encephalopathy.123 In a paper 
by Solomon and colleagues, four out of four cases 
with Alzheimer Type II astrocytes had chronic liver 
disease or alcohol use disorder.97 The relative con-
tribution of hepatic encephalopathy to cases cur-
rently ascribed as septic or para-infectious encepha-
lopathy remains to be seen. 
9. Conclusions 
Systemic dysfunction and viral infection of the 
CNS can cause a wide range of COVID-19 related 
neuropathological changes. The incidence of neuro-
pathological findings should be viewed with caution 
given great variability in what tissues were studied 
and what types of ancillary studies were (or were 
not) performed. Inflammatory changes were re-
ported in a high percentage of cases in some series 
but not in others, at least in part due to the use of 
immunostaining; however, the lack of controls in 
most of these studies limit interpretation of these 
findings. Selection or referral bias, the decedent’s 
co-morbidities, therapies given, patient’s genetic 
background, immune status, immunization status 
and perhaps viral strains of SARS-CoV-2 may also 
contribute to differences and will need to be dis-
sected out in the future. Whether or how much of 
the inflammatory changes seen are due to autoim-
mune phenomena versus direct viral infection or 
other causes remains to be resolved. The presence 
of microglial nodules and detectable virus are indic-
ative of viral meningoencephalitis in some cases; a 
predilection for the medulla perhaps with compro-
mise of respiratory and cardiovascular control cen-
ters may compound the COVID-19 patient’s often al-
ready tenuous cardiorespiratory function. While 
there is evidence for an olfactory route of infection, 
it is unclear whether this is the major mechanism of 
CNS infection given that the virus is rarely detecta-
ble in the olfactory bulb. Cerebral endothelial infec-
tion is also present and a hematogenous route of in-
fection is therefore plausible perhaps even com-
mon. Data on where the virus is detectable in the 
brain is limited as studies have focused on the 
frontal lobe and brainstem. It would not be surpris-
ing to find a greater extent of infection than cur-
rently confirmed. It should be kept in mind that the 
sensitivity of virus detection is suboptimal given that 
most samples are derived from autopsies. Lastly, it 
is notable that inflammation does not always coin-
cide with virus localization, raising the concern that 
the virus may be evading the immune response in 
the CNS. Whether the CNS is a potential long-term 
reservoir of virus and a contributor to “Long COVID” 
remains to be seen. Lastly, increased risk for vascu-
lar dementia or neurodegenerative disorders are hy-
pothetical concerns that may need to be addressed 
at a later time. 
Free Neuropathology 2:2 (2021) Jerry J. Lou et al 





This work was supported in part by NIMH 
2U24MH10092 and U01 MH083500 (S. Magaki, E. 
Singer, W. Yong) and in part by the UCLA Broad Stem 
Cell Research Center COVID 19 Research Award 
OCRC #20-70 (H.V. Vinters, S. Magaki, and T. Zhang). 
References
1. Naming the coronavirus disease (COVID-19) and the virus that causes 




2. Weekly epidemiological update - 29 December 2020. World Health 
Organization. Accessed December 30, 2020. 
https://www.who.int/publications/m/item/weekly-epidemiological-
update---29-december-2020 
3. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of 
human coronaviruses. Int J Biol Sci. 2020;16(10):1686-1697. 
doi:10.7150/ijbs.45472 
4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients 
with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. 
doi:10.1056/NEJMoa2001017 
5. Caly L, Druce J, Roberts J, et al. Isolation and rapid sharing of the 2019 
novel coronavirus (SARS-CoV-2) from the first patient diagnosed with 
COVID-19 in Australia. Med J Aust. 2020;212(10):459-462. 
doi:10.5694/mja2.50569 
6. Gulholm T, Basile K, Kok J, Chen S, Rawlinson W. Laboratory diagnosis 
of severe acute respiratory syndrome coronavirus 2. Pathology. 
2020;52(7):745-753. doi:10.1016/j.pathol.2020.09.011 
7. Koyama T, Platt D, Parida L. Variant analysis of SARS-cov-2 genomes. 
Bull World Health Organ. 2020;98(7):495-504. 
doi:10.2471/BLT.20.253591 
8. Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 
genome, structure, evolution, pathogenesis and therapies: Structural 
genomics approach. Biochim Biophys acta Mol basis Dis. 
2020;1866(10):165878. doi:10.1016/j.bbadis.2020.165878 
9. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-
CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat 
Commun. 2020;11(1). doi:10.1038/s41467-020-15562-9 
10. Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 
mutation hot spots include a novel RNA-dependent-RNA polymerase 
variant. J Transl Med. 2020;18(1):1-9. doi:10.1186/s12967-020-02344-6 
11. Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology 
of SARS-CoV-2. Curr Biol. 2020;30(15):R849-R857. doi:10.1016
/j.cub.2020.06.031 
12. Rowland-Jones S, Andrews SM. Recent advances in understanding 
HIV evolution. F1000Research. 2017;6(0):1-7. doi:10.12688
/f1000research.10876.1 
13. Nobusawa E, Sato K. Comparison of the Mutation Rates of Human 
Influenza A and B Viruses. J Virol. 2006;80(7):3675-3678. 
doi:10.1128/jvi.80.7.3675-3678.2006 
14. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting 
Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin 
System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ 
Res. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015 
15. Wang K, Chen W, Zhang Z, et al. CD147-spike protein is a novel route 
for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 
2020;5(1):283. doi:10.1038/s41392-020-00426-x 
16. Fernández-Atucha A, Izagirre A, Fraile-Bermúdez AB, et al. Sex 
differences in the aging pattern of renin-angiotensin system serum 
peptidases. Biol Sex Differ. 2017;8(1). doi:10.1186/s13293-017-0128-8 
17. Hu Y, Li X, Wu N, Wang N, Qui C, Li J. Study on the correlation among 
sex, age, and the activity of ACE, ACE2 and the ratio of ACE/ACE2. J 
Qiqihar Med Coll. 2018;39(8):884-887. doi:10.3969/j.issn.1002-
1256.2018.08.005 
18. Liu Y, Zhao L, Zhang Q, Zhang L, Ren G. Effect of long-term smoking 
on expressiong of serum ACE and ACE2 as well as its significance. J 
Taishan Med Coll. 2019;40(4):258-260. doi:10.3969/j.issn.1004-
7115.2019.04.007 
19. Smith JC, Sausville EL, Girish V, et al. Cigarette Smoke Exposure and 
Inflammatory Signaling Increase the Expression of the SARS-CoV-2 
Receptor ACE2 in the Respiratory Tract. Dev Cell. 2020;53(5):514-
529.e3. doi:https://doi.org/10.1016/j.devcel.2020.05.012 
20. Bernardi S, Toffoli B, Zennaro C, et al. High-salt diet increases 
glomerular ACE/ACE2 ratio leading to oxidative stress and kidney 
damage. Nephrol Dial Transplant. 2012;27(5):1793-1800. 
doi:10.1093/ndt/gfr600 
21. Lavrentyev EN, Malik KU. High glucose-induced Nox1-derived 
superoxides downregulate PKC-βII, which subsequently decreases ACE2 
expression and ANG(1-7) formation in rat VSMCs. Am J Physiol - Hear 
Circ Physiol. 2009;296(1):106-118. doi:10.1152/ajpheart.00239.2008 
22. Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: 
properties and future directions. J Neurochem. 2008;107(6):1482-1494. 
doi:10.1111/j.1471-4159.2008.05723.x 
23. Brann D, Tsukahara T, Weinreb C, et al. Non-neuronal expression of 
SARS-CoV-2 entry genes in the olfactory system suggests mechanisms 
underlying COVID-19-associated anosmia. Sci Adv. 
2020;6(31):eabc5801. doi:10.1126/sciadv.abc5801 
24. Chen M, Shen W, Rowan NR, et al. Elevated ACE2 expression in the 
olfactory neuroepithelium: implications for anosmia and upper 
respiratory SARS-CoV-2 entry and replication. Eur Respir J. 
2020;56(3):2001948. doi:10.1183/13993003.01948-2020 
25. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of 
patients with COVID-19 in Germany: a post-mortem case series. Lancet 
Neurol. 2020;19(11). doi:10.1016/S1474-4422(20)30308-2 
26. Wang K, Chen W, Zhou Y Sen, et al. SARS-CoV-2 invades host cells via 
a novel route: CD147-spike protein. bioRxiv. Published online January 1, 
2020:2020.03.14.988345. doi:10.1101/2020.03.14.988345 
27. Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates 
SARS-CoV-2 cell entry and provides a possible pathway into the central 
nervous system. bioRxiv. Published online January 1, 
2020:2020.06.07.137802. doi:10.1101/2020.06.07.137802 
28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell 
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 
Free Neuropathology 2:2 (2021) Jerry J. Lou et al 




Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. 
doi:10.1016/j.cell.2020.02.052 
29. Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 
promote SARS-CoV-2 infection of human small intestinal enterocytes. 
Sci Immunol. 2020;5(47):eabc3582. doi:10.1126/sciimmunol.abc3582 
30. COVID-19 RT-PCR test - Emergency Use Authorization (EUA) 
summary. Laboratory Corporation of America. Accessed September 2, 
2020. https://www.fda.gov/media/136151/download 
31. Long C, Xu H, Shen Q, et al. Diagnosis of the Coronavirus disease 
(COVID-19): rRT-PCR or CT? Eur J Radiol. 2020;126:108961. 
doi:10.1016/j.ejrad.2020.108961 
32. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing 
in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 
Cases. Radiology. 2020;296(2):E32-E40. doi:10.1148
/radiol.2020200642 
33. Moriguchi T, Harii N, Goto J, et al. A first Case of 
Meningitis/Encephalitis associated with SARS-Coronavirus-2. Int J Infect 
Dis. 2020;94:55-58. doi:10.1016/j.ijid.2020.03.062 
34. Perera RAPM, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and 
Subgenomic RNA for Respiratory Specimens from Patients with Mild 
Coronavirus Disease. Emerg Infect Dis J. 2020;26(11):2701. 
doi:10.3201/eid2611.203219 
35. Dai W-C, Zhang HW, Yu J, et al. CT Imaging and Differential Diagnosis 
of COVID-19. Can Assoc Radiol J. 2020;71(2):195-200. 
doi:10.1177/0846537120913033 
36. Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to 
Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis an Off 
Publ Infect Dis Soc Am. Published online March 2020. 
doi:10.1093/cid/ciaa310 
37. Gauger PC, Vincent AL. Serum Virus Neutralization Assay for 
Detection and Quantitation of Serum Neutralizing Antibodies to 
Influenza A Virus in Swine. Methods Mol Biol. 2020;2123:321-333. 
doi:10.1007/978-1-0716-0346-8_23 
38. Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory 
Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus 
Disease 2019 Patients. Emerg Infect Dis. 2020;26(7). 
doi:10.3201/eid2607.200841 
39. Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and 
IgG responses in COVID-19 patients. Emerg Microbes Infect. 
2020;9(1):940-948. doi:10.1080/22221751.2020.1762515 
40. Krammer F, Simon V. Serology assays to manage COVID-19. Science. 
2020;368(6495):1060-1061. doi:10.1126/science.abc1227 
41. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. 
Pathophysiology, Transmission, Diagnosis, and Treatment of 
Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 
2020;324(8):782-793. doi:10.1001/jama.2020.12839 
42. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 
associated with acute respiratory distress syndrome. Lancet Respir Med. 
2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X 
43. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between 
inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-e47. 
doi:10.1016/S2213-2600(20)30216-2 
44. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of 
Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. 
JAMA Neurol. 2020;77(6):683-690. doi:10.1001/jamaneurol.2020.1127 
45. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and 
gustatory dysfunctions as a clinical presentation of mild-to-moderate 
forms of the coronavirus disease (COVID-19): a multicenter European 
study. Eur Arch Oto-Rhino-Laryngology. 2020;277(8):2251-2261. 
doi:10.1007/s00405-020-05965-1 
46. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of 
chemosensory dysfunction and COVID-19 in patients presenting with 
influenza-like symptoms. Int Forum Allergy Rhinol. 2020;10(7):806-813. 
doi:10.1002/alr.22579 
47. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe 
SARS-CoV-2 Infection. N Engl J Med. 2020;382(21):2268-2270. 
doi:10.1056/nejmc2008597 
48. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum 
of COVID-19 neurology: clinical, radiological and laboratory findings. 
Brain. 2020;143(10):3104-3120. doi:10.1093/brain/awaa240 
49. Paolo G. Does COVID-19 cause permanent damage to olfactory and 
gustatory function? Med Hypotheses. 2020;143:110086. 
doi:10.1016/j.mehy.2020.110086 
50. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following 
new onset anosmia during the COVID-19 pandemic – an observational 
cohort study. J Otolaryngol - Head Neck Surg. 2020;49(1):26. 
doi:10.1186/s40463-020-00423-8 
51. Whitcroft KL, Hummel T. Olfactory Dysfunction in COVID-19: 
Diagnosis and Management. JAMA. 2020;323(24):2512-2514. 
doi:10.1001/jama.2020.8391 
52. Paderno A, Mattavelli D, Rampinelli V, et al. Olfactory and Gustatory 
Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized 
Subjects. Otolaryngol Head Neck Surg. 2020;163(6):1144-1149. 
doi:10.1177/0194599820939538 
53. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal 
SARS-CoV-2 invasion as a port of central nervous system entry in 
individuals with COVID-19. Nat Neurosci. Published online 2020. 
doi:10.1038/s41593-020-00758-5 
54. Morbini P, Benazzo M, Verga L, et al. Ultrastructural Evidence of 
Direct Viral Damage to the Olfactory Complex in Patients Testing 
Positive for SARS-CoV-2. JAMA Otolaryngol Neck Surg. 
2020;146(10):972-973. doi:10.1001/jamaoto.2020.2366 
55. Merkler AE, Parikh NS, Mir S, et al. Risk of Ischemic Stroke in Patients 
with Coronavirus Disease 2019 (COVID-19) vs Patients with Influenza. 
JAMA Neurol. 2020;77(11):1–7. doi:10.1001/jamaneurol.2020.2730 
56. Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and Stroke in a New York 
Healthcare System. Stroke. 2020;51(7):2002-2011. 
doi:10.1161/STROKEAHA.120.030335 
57. Jain R, Young M, Dogra S, et al. COVID-19 related neuroimaging 
findings: A signal of thromboembolic complications and a strong 
prognostic marker of poor patient outcome. J Neurol Sci. 
2020;414:116923. doi:10.1016/j.jns.2020.116923 
58. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting 
Feature of COVID-19 in the Young. N Engl J Med. 2020;382(20):e60-e60. 
doi:10.1056/NEJMc2009787 
59. National Hospital Ambulatory Medical Care Survey: 2017 Emergency 
Department Summary Tables. Centers for Disease Control and 
Prevention. Accessed January 10, 2021. https://www.cdc.gov
/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf 
60. Dogra S, Jain R, Cao M, et al. Hemorrhagic stroke and anticoagulation 
in COVID-19. J Stroke Cerebrovasc Dis. 2020;29(8):104984. 
doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104984 
61. Wu Z, McGoogan JM. Characteristics of and Important Lessons From 
the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary 
of a Report of 72 314 Cases From the Chinese Center for Disease Control 
Free Neuropathology 2:2 (2021) Jerry J. Lou et al 




and Prevention. JAMA. Published online February 2020. 
doi:10.1001/jama.2020.2648 
62. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its 
effects in patients infected with SARS-CoV-2: a systematic review and 
meta-analysis. Int J Infect Dis  IJID  Off Publ  Int Soc Infect Dis. 
2020;94:91-95. doi:10.1016/j.ijid.2020.03.017 
63. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased 
patients with coronavirus disease 2019: retrospective study. BMJ. 
2020;368:m1091. doi:10.1136/bmj.m1091 
64. Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe 
disease and death. BMJ. 2020;368:m1198. doi:10.1136/bmj.m1198 
65. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of 
patients with COVID-19: evidence from meta-analysis. Aging (Albany 
NY). 2020;12(7):6049-6057. doi:10.18632/aging.103000 
66. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity 
in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 
Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 
2020;28(7):1195-1199. doi:10.1002/oby.22831 
67. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger 
than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect 
Dis. Published online April 2020. doi:10.1093/cid/ciaa415 
68. Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO 
blood group with indices of disease severity and multiorgan dysfunction 
in COVID-19. Blood Adv. 2020;4(20):4981-4989. doi:10.1182
/bloodadvances.2020002623 
69. Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in 
patients with COVID-19. Ann Hematol. 2020;99(9):2113-2118. 
doi:10.1007/s00277-020-04169-1 
70. Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome 
following COVID-19: new infection, old complication? J Neurol. 
2020;(Table 1):1-3. doi:10.1007/s00415-020-09849-6 
71. Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome 
Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-2576. 
doi:10.1056/NEJMc2009191 
72. Dalakas MC. Guillain-Barré syndrome: The first documented COVID-
19–triggered autoimmune neurologic disease. Neurol - Neuroimmunol 
Neuroinflammation. 2020;7(5):e781. doi:10.1212
/NXI.0000000000000781 
73. Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated 
Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 
2020;62(4):485-491. doi:10.1002/mus.27024 
74. Trujillo Gittermann LM, Valenzuela Feris SN, von Oetinger Giacoman 
A. Relation between COVID-19 and Guillain-Barré syndrome in adults. 
Systematic review TT - Relación entre COVID-19 y síndrome de Guillain-
Barré en adultos. Revisión sistemática. Neurologia. 2020;35(9):646-654. 
doi:10.1016/j.nrl.2020.07.004 
75. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-
Barré syndrome spectrum associated with COVID-19: an up-to-date 
systematic review of 73 cases. J Neurol. Published online August 25, 
2020:1-38. doi:10.1007/s00415-020-10124-x 
76. Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an 
overview of the reports. Neurol Sci. 2020;41(11):3149-3156. 
doi:10.1007/s10072-020-04693-y 
77. Ehrenfeld M, Tincani A, Andreoli L, et al. COVID-19 and 
autoimmunity. Autoimmun Rev. 2020;19(8):102597. 
doi:10.1016/j.autrev.2020.102597 
78. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher 
Syndrome and polyneuritis cranialis in COVID-19. Neurology. 
2020;241:10.1212/WNL.0000000000009619. 
doi:10.1212/wnl.0000000000009619 
79. von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of 
pronounced brain involvement in fatal COVID-19 outcomes. Lancet 
(London, England). 2020;395(10241):e109. doi:10.1016/S0140-
6736(20)31282-4 
80. Cavalcanti D, Raz E, Shapiro M, et al. Cerebral Venous Thrombosis 
associated with COVID-19. Am J Neuroradiol. 2020;41(8):1-7. 
doi:10.3174/ajnr.a6644 
81. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-
19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging 
Features. Radiology. 2020;296(2):E119-E120. doi:10.1148
/radiol.2020201187 
82. Dixon L, Varley J, Gontsarova A, et al. COVID-19-related acute 
necrotizing encephalopathy with brain stem involvement in a patient 
with aplastic anemia. Neurol - Neuroimmunol Neuroinflammation. 
2020;7(5):e789. doi:10.1212/NXI.0000000000000789 
83. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, 
Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and 
acute disseminated encephalomyelitis (ADEM)-like pathology. Acta 
Neuropathol. 2020;140(1):1-6. doi:10.1007/s00401-020-02166-2 
84. Jensen MP, Le Quesne J, Officer-Jones L, et al. Neuropathological 
findings in two patients with fatal COVID-19. Neuropathol Appl 
Neurobiol. 2020;n/a(n/a). doi:10.1111/nan.12662 
85. Jaunmuktane Z, Mahadeva U, Green A, et al. Microvascular injury 
and hypoxic damage: emerging neuropathological signatures in COVID-
19. Acta Neuropathol. 2020;140(3):397-400. doi:10.1007/s00401-020-
02190-2 
86. Deigendesch N, Sironi L, Kutza M, et al. Correlates of critical illness-
related encephalopathy predominate postmortem COVID-19 
neuropathology. Acta Neuropathol. 2020;140(4):583-586. 
doi:10.1007/s00401-020-02213-y 
87. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in 
human and mouse brain. bioRxiv. Published online September 8, 
2020:2020.06.25.169946. doi:10.1101/2020.06.25.169946 
88. Schurink B, Roos E, Radonic T, et al. Viral presence and 
immunopathology in patients with lethal COVID-19: a prospective 
autopsy cohort study. The Lancet Microbe. 2020;1(7):e290-e299. 
doi:10.1016/S2666-5247(20)30144-0 
89. Al-Dalahmah O, Thakur KT, Nordvig AS, et al. Neuronophagia and 
microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage. 
Acta Neuropathol Commun. 2020;8(1):147. doi:10.1186/s40478-020-
01024-2 
90. Hernández-Fernández F, Valencia HS, Barbella-Aponte RA, et al. 
Cerebrovascular disease in patients with COVID-19: neuroimaging, 
histological and clinical description. Brain. 2020;143(10):3089-3103. 
doi:10.1093/brain/awaa239 
91. Fabbri VP, Foschini MP, Lazzarotto T, et al. Brain ischemic injury in 
COVID-19-infected patients: a series of 10 post-mortem cases. Brain 
Pathol. Published online October 1, 2020. doi:10.1111/bpa.12901 
92. Patel SD, Kollar R, Troy P, et al. Malignant Cerebral Ischemia in A 
COVID-19 Infected Patient: Case Review and Histopathological Findings. 
J Stroke Cerebrovasc Dis. 2020;29(11):105231. doi:10.1016
/j.jstrokecerebrovasdis.2020.105231 
93. Patel HN, Syed A, Lobel JS, et al. Cerebellar infarction requiring 
surgical decompression in patient with COVID 19 pathological analysis 
and brief review. Interdiscip Neurosurg Adv Tech case Manag. 
2020;22:100850. doi:10.1016/j.inat.2020.100850 
Free Neuropathology 2:2 (2021) Jerry J. Lou et al 




94. Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: 
targeting of endothelial cells renders a complex disease with thrombotic 
microangiopathy and aberrant immune response. The Mount Sinai 
COVID-19 autopsy experience. medRxiv. Published online January 1, 
2020:2020.05.18.20099960. doi:10.1101/2020.05.18.20099960 
95. Remmelink M, De Mendoca R, D’Haene N, et al. Unspecific post-
mortem findings despite multiorgan 1 viral spread in COVID-19 patients. 
Crit Care. 2020;21(1):495. doi:10.1186/s13054-020-03218-5 
96. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system 
involvement by severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2). J Med Virol. 2020;92(7):699-702. doi:10.1002/jmv.25915 
97. Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological 
Features of Covid-19. N Engl J Med. 2020;383(10):989-992. 
doi:10.1056/NEJMc2019373 
98. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings 
and viral tropism in UK patients with severe fatal COVID-19: a post-
mortem study. The Lancet Microbe. 2020;1(6):e245-e253. 
doi:https://doi.org/10.1016/S2666-5247(20)30115-4 
99. Kantonen J, Mahzabin S, Mäyränpää MI, et al. Neuropathologic 
features of four autopsied COVID-19 patients. Brain Pathol. Published 
online August 6, 2020. doi:10.1111/bpa.12889 
100. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich 
S. Neuropathogenesis and Neurologic Manifestations of the 
Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA 
Neurol. 2020;77(8):1018-1027. doi:10.1001/jamaneurol.2020.2065 
101. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous 
System. Cell. 2020;183(1):16-27.e1. doi:10.1016/j.cell.2020.08.028 
102. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe 
acute respiratory syndrome coronavirus infection causes neuronal 
death in the absence of encephalitis in mice transgenic for human ACE2. 
J Virol. 2008;82(15):7264-7275. doi:10.1128/JVI.00737-08 
103. Hao XY, Lv Q, Li F Di, Xu YF, Gao H. The characteristics of hDPP4 
transgenic mice subjected to aerosol MERS coronavirus infection via an 
animal nose-only exposure device. Anim Model Exp Med. 2019;2(4):269-
281. doi:10.1002/ame2.12088 
104. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging 
Alteration of the Brain in a Patient With Coronavirus Disease 2019 
(COVID-19) and Anosmia. JAMA Neurol. 2020;77(8):1028-1029. 
doi:10.1001/jamaneurol.2020.2125 
105. Fodoulian L, Tuberosa J, Rossier D, et al. SARS-CoV-2 Receptors and 
Entry Genes Are Expressed in the Human Olfactory Neuroepithelium 
and Brain. iScience. 2020;23(12):101839. doi:10.1016
/j.isci.2020.101839 
106. Nampoothiri S, Sauve F, Ternier G, et al. The hypothalamus as a hub 
for putative SARS-CoV-2 brain infection. bioRxiv. Published online 
January 1, 2020:2020.06.08.139329. doi:10.1101/2020.06.08.139329 
107. Kim WK, Corey S, Alvarez X, Williams K. Monocyte/macrophage 
traffic in HIV and SIV encephalitis. J Leukoc Biol. 2003;74(5):650-656. 
doi:10.1189/jlb.0503207 
108. Trojanowicz B, Ulrich C, Kohler F, et al. Monocytic angiotensin-
converting enzyme 2 relates to atherosclerosis in patients with chronic 
kidney disease. Nephrol Dial Transplant. 2017;32(2):287-298. 
doi:10.1093/ndt/gfw206 
109. Salamanna F, Maglio M, Landini MP, Fini M. Body Localization of 
ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front Med. 
2020;7:935. 
https://www.frontiersin.org/article/10.3389/fmed.2020.594495 
110. Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the 
central nervous system: host-virus stand-off. Nat Rev Microbiol. 
2006;4(2):121-132. doi:10.1038/nrmicro1343 
111. Neumann B, Schmidbauer ML, Dimitriadis K, et al. Cerebrospinal 
fluid findings in COVID-19 patients with neurological symptoms. J Neurol 
Sci. 2020;418:117090. doi:10.1016/j.jns.2020.117090 
112. Espíndola O de M, Siqueira M, Soares CN, et al. Patients with 
COVID-19 and neurological manifestations show undetectable SARS-
CoV-2 RNA levels in the cerebrospinal fluid. Int J Infect Dis. 2020;96:567-
569. doi:10.1016/j.ijid.2020.05.123 
113. Bellon M, Schweblin C, Lambeng N, et al. Cerebrospinal fluid 
features in SARS-CoV-2 RT-PCR positive patients. Clin Infect Dis. 
Published online August 8, 2020:ciaa1165. doi:10.1093/cid/ciaa1165 
114. Hung ECW, Chim SSC, Chan PKS, et al. Detection of SARS 
coronavirus RNA in the cerebrospinal fluid of a patient with severe acute 
respiratory syndrome. Clin Chem. 2003;49(12):2108-2109. 
doi:10.1373/clinchem.2003.025437 
115. Zhou L, Zhang M, Wang J, Gao J. SARS-Cov-2: Underestimated 
damage to nervous system. Travel Med Infect Dis. 2020;36:101642. 
doi:10.1016/j.tmaid.2020.101642 
116. Virhammar J, Kumlien E, Fällmar D, et al. Acute necrotizing 
encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. 
Neurology. 2020;95(10):445-449. 
doi:10.1212/WNL.0000000000010250 
117. Chen G, Wu D, Guo W, et al. Clinical and immunological features of 
severe and moderate coronavirus disease 2019. J Clin Invest. 
2020;130(5):2620-2629. doi:10.1172/JCI137244 
118. Huang C, Wang Y, Li X, et al. Clinical features of patients infected 
with 2019 novel coronavirus in Wuhan, China. Lancet. 
2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 
119. Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-
CoV-2. Clin Chim Acta. 2020;509:280-287. doi:https://doi.org
/10.1016/j.cca.2020.06.017 
120. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-
19-associated coagulopathy: evidence from a single-centre, cross-
sectional study. Lancet Haematol. 2020;7(8):e575-e582. 
doi:10.1016/S2352-3026(20)30216-7 
121. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on 
recognition and management of coagulopathy in COVID-19. J Thromb 
Haemost. 2020;18(5):1023-1026. doi:10.1111/jth.14810 
122. Yaqinuddin A, Kvietys P, Kashir J. COVID-19: Role of neutrophil 
extracellular traps in acute lung injury. Respir Investig. 2020;58(5):419-
420. doi:10.1016/j.resinv.2020.06.001 
123. Agarwal AN, Mais DD. Sensitivity and Specificity of Alzheimer Type 
II Astrocytes in Hepatic Encephalopathy. Arch Pathol Lab Med. 
2019;143(10):1256-1258. doi:10.5858/arpa.2018-0455-OA 
 
 
